Fiasp (insulin aspart) is a brand-name medication prescribed to help manage blood sugar levels in adults and children with diabetes. As with other drugs, Fiasp can cause side effects, such as low ...
For information about Fiasp dosing, including the drug’s strength and how to take the medication, keep reading. For a comprehensive look at Fiasp, see this article. This article describes typical ...
The FDA has expanded the indication for Fiasp (insulin aspart injection; Novo Nordisk) 100 Units/mL to include use in insulin infusion pumps to improve glycemic control in adults with type 1 or type 2 ...
The approval was based on data from an active-controlled, treat-to-target trial (Onset7) that included 777 pediatric patients (aged 2 to 17 years) with type 1 diabetes. The Food and Drug ...
The FDA expanded the use of Fiasp, a fast-acting insulin aspart injection, in children as young as 2 years to treat diabetes. First approved for adults in 2017, Novo Nordisk said it is the only ...
Bagsværd, Denmark, 29 September 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Fiasp ® (fast-acting insulin aspart), a new fast-acting mealtime insulin ...
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System) ...
Novo Nordisk has submitted applications to both US and EU regulators for use of its fast-acting insulin Fiasp in children. Novo Nordisk has submitted label updates to the European Medicines Agency ...
Bagsværd, Denmark, 10 January 2017 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Fiasp ® for the treatment of diabetes in adults. The ...
Medicare, the health insurance program for people over 65 years old, said it will start negotiating prices on 10 drugs, part of its mandate under the Inflation Reduction Act to lower prescription ...
The active ingredient in Fiasp is insulin aspart. (An active ingredient is what makes a drug work.) Fiasp is a biologic drug, which means it’s made from living cells. Fiasp comes as a liquid solution ...
The approval was based on data from an active-controlled, treat-to-target trial (Onset7) that included 777 pediatric patients (aged 2 to 17 years) with type 1 diabetes. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results